 Akero Therapeutics Inc NASDAQ: AKRO has announced full results of the main portion of its Phase 2a BALANCED trial of efruxifermin EFX in NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The manuscript provides a comprehensive analysis showing that pre-cirrhotic NASH patients treated for 16 weeks with EFX achieved substantial reductions in liver fat, associated with decreases in markers of liver injury and inflammation and reversal of fibrosis. 